Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Zolgensma
Zolgensma
Novartis used manipulated data in winning Zolgensma approval, FDA says
Biopharma Dive
Wed, 08/7/19 - 10:57 am
Novartis
FDA
Zolgensma
data
spinal muscular atrophy
gene therapy
AveXis
Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU
RAPS.org
Mon, 07/29/19 - 11:19 pm
Novartis
Zolgensma
CHMP
Europe
SMA
24 insurers have policies on coverage of world's most expensive drug
Beckers Hospital Review
Mon, 07/22/19 - 08:13 pm
Novartis
payers
insurance
Medicaid
SMA
drug pricing
Zolgensma
Payers, patients coming on board for Novartis’ Zolgensma
BioCentury
Thu, 07/18/19 - 05:58 pm
Novartis
Zolgensma
SMA
gene therapy
payers
patients
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts
Fierce Pharma
Wed, 07/3/19 - 10:38 am
Novartis
Zolgensma
drug pricing
SMA
gene therapy
payers
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
Fierce Pharma
Thu, 06/13/19 - 12:14 pm
drug pricing
GoodRx
Novartis
Spark Therapeutics
Zolgensma
Luxturna
The gene therapy era has arrived. So have the challenges.
Biopharma Dive
Sun, 06/9/19 - 01:43 pm
cell therapy
gene therapy
FDA
regulatory
Novartis
Zolgensma
Is $2.1 million too much for a drug? For affected parents, there is no debate
Stat
Mon, 06/3/19 - 11:28 am
Novartis
drug pricing
Zolgensma
SMA
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
Motley Fool
Fri, 05/31/19 - 11:53 pm
Novartis
Zolgensma
SMA
gene therapy
Novartis gene therapy approved, but will come at cost of more than $2 million
Biopharma Dive
Fri, 05/24/19 - 11:45 pm
SMA
Novartis
drug pricing
Zolgensma
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Yahoo/Reuters
Thu, 05/23/19 - 09:48 am
Novartis
Pharma CEOs
Vas Narasimhan
gene therapy
SMA
drug pricing
Zolgensma
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Mon, 05/6/19 - 09:52 pm
Novartis
FDA
spinal muscular atrophy
Zolgensma
AveXis
Biogen
Spinraza
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Sun, 05/5/19 - 06:51 pm
Novartis
gene therapy
Zolgensma
FDA
spinal muscular atrophy
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
Thu, 05/2/19 - 11:00 am
gene therapy
SMA
spinal muscular atrophy
Novartis
Zolgensma
Orphan drugs market to soar to $224bn by 2024
PM Live
Fri, 04/26/19 - 08:18 pm
orphan drugs
Zolgensma
LentiGlobin
Evaluate Pharma
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Yahoo/Reuters
Wed, 04/24/19 - 12:02 pm
Novartis
Zolgensma
gene therapy
drug pricing
spinal muscular atrophy
Novartis' star gene therapy faces potential safety issue following a recent infant death in study
Endpoints
Sun, 04/21/19 - 12:23 am
Novartis
Zolgensma
SMA
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Wed, 04/17/19 - 10:41 pm
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »